BioPharmSignal logoBioPharmSignal

Biotech News

BioCryst to Report First Quarter 2026 Financial Results on May 6

BioCryst Pharmaceuticals (BCRX)BioCryst PharmaceuticalsEarnings

RESEARCH TRIANGLE PARK, N.C., April 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2026 financial results on Wednesday, May 6, 2026. BioCryst management will host a conference call and webcast at 8:30 a.m.

Related news

BCRXBioCryst Pharmaceuticals2026-07-22 11:00 EST

BioCryst to Report Second Quarter 2026 Financial Results on August 5

BCRXBioCryst Pharmaceuticals2026-05-06 11:00 EST

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

CRISCuris2026-05-05 21:11 EST

Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026

ETONEton Pharmaceuticals2026-08-03 10:50 EST

Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

KRYSKrystal Biotech2026-07-23 21:00 EST

Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026

PTCTPTC Therapeutics, Inc.2026-07-16 12:00 EST

PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026

CRNXCrinetics Pharmaceuticals2026-06-30 20:05 EST

Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026

ETONEton Pharmaceuticals2026-05-14 20:05 EST

Eton Pharmaceuticals Reports First Quarter 2026 Financial Results

MGTXMeiraGTx2026-05-14 12:00 EST

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

TARAProtara Therapeutics2026-05-13 12:00 EST

Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

View all latest news

BioCryst Pharmaceuticals

Rare-Disease Drug Development BioCryst Pharmaceuticals discovers, develops and commercializes small-molecule medicines for rare diseases. Its portfolio combines a marketed hereditary angioedema franchise with clinical programs targeting additional protein-mediated disorders. ORLADEYO Commercial Franchise ORLADEYO is an oral preventive...

Recent company news

BCRXBioCryst Pharmaceuticals2026-08-05 11:00 EST

BioCryst Reports Second Quarter 2026 Financial Results

BCRXBioCryst Pharmaceuticals2026-07-22 11:00 EST

BioCryst to Report Second Quarter 2026 Financial Results on August 5

BCRXBioCryst Pharmaceuticals2026-07-15 11:00 EST

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

BCRXBioCryst Pharmaceuticals2026-07-02 11:00 EST

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BCRXBioCryst Pharmaceuticals2026-06-29 11:00 EST

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

Stock data

Close
9.30 USD
Market cap
2.12B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States